Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

3.130 -0.100 (-3.10%)
Delayed Quote Updated: 2:54 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ARDX
From DJS Law Group
Via Business Wire
News headline image
Ardelyx Targets $500M Revenue This Year, Profitability by 2027 ↗
Ardelyx (NASDAQ:ARDX) expects to generate close to $500 million in revenue this year and reach profitability in 2027, supported by continued growth of its IBS-C treatment IBSRELA and hyperphosphatemia... 
Via MarketBeat
News headline image
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
Ardelyx (NASDAQ:ARDX) Plunges After Q2 Miss and Guidance Cut ↗
Via Chartmill
Ardelyx Inc (NASDAQ:ARDX) Reports Strong Q1 Revenue Beat as IBSRELA Momentum Accelerates ↗
Via Chartmill
News headline image
ARDX SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ardelyx (NASDAQ: ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
ARDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ardelyx (NASDAQ: ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Investor Alert: Robbins LLP Informs Investors of the Ardelyx, Inc. Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
ARDX INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Ardelyx, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm
From Holzer & Holzer
Via GlobeNewswire
News headline image
Ardelyx to Participate in Upcoming Investor Conferences
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Ardelyx (ARDX) Q2 2026 Earnings Call Transcript ↗
Record revenue masks payer headwinds forcing IBSRELA guidance cuts. 
Via The Motley Fool
Topics Earnings Economy
News headline image
Ardelyx Q2 Earnings Call Highlights ↗
Ardelyx (NASDAQ:ARDX) reported second-quarter product revenue of $118 million, up 31% from a year earlier and representing the company’s largest quarterly revenue total to date. The company lowered its... 
Via MarketBeat
Topics Earnings
News headline image
Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction ↗
This biotech specializing in gastrointestinal and cardiorenal therapies reported a notable insider sale following strong 1-year returns. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach ↗
Ardelyx (NASDAQ:ARDX) executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to... 
Via MarketBeat
News headline image
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx (ARDX) Q1 2026 Earnings Transcript ↗
Ardelyx (ARDX) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings
Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx President and CEO Sells 41,000 Shares for $243,000 ↗
This biotech innovator in gastrointestinal and kidney therapies reported a notable insider sale amid routine portfolio adjustments. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
Award recognizes leading chronic kidney disease advocates 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment 
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.